Healthcare • NASDAQ
According to Zyberno, MASIMO CORP (MASI) is not a buy — AVERAGE BUSINESS (53/100) with a negative Margin of Safety of -43.1% and a Brina Gap of -18.4% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, MASIMO CORP (MASI) trades at $179.95 against an estimated intrinsic value per share of $125.72 — a -43.1% Margin of Safety based on Owner Earnings of $210.90M TTM, projected at 70.5% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -18.4% weakens the case: based on the company's ROIC (21.9%) and reinvestment rate (-7.9%), the business can fundamentally grow at -1.7% — but the current enterprise value implies the market expects 16.7%. This places MASI in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 11.7% annually.
Over the trailing twelve months, MASI generated $210.90M in Owner Earnings. Capital was deployed as follows: $100.00K returned via share buybacks, $21.10M invested in capital expenditures. Reinvestment rate: -7.9%. Owner Earnings have grown at 70.5% annually over the trailing five years using log-linear regression.